Objective:To observe the clinical efficacy of Suhuang Zhike Capsule combined with terbutaline and montelukast in the treatment of chronic cough variant asthma(CVA).Methods:Sixty patients were randomly divided into a treatment group and a control group,with 30 patients in each group.Both groups received nebulized terbutaline and oral montelukast,while the treatment group additionally received Suhuang Zhike Capsule.Results:After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP)and eosinophil(EOS)were lower in the treatment group than in the control group(P<0.05).The time for cough relief was shorter in the treatment group(P<0.05).The total effective rate was higher in the treatment group than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion:The combination of Suhuang Zhike Capsule,montelukast,and terbutaline is effective in treating CVA,with faster improvement in blood inflammatory markers and cough symptoms,without increasing the incidence of adverse events.
维普
万方数据